Ion channels continue to be an important therapeutic target for a range of indications including arrhythmia, hypertension, local anesthesia, pain, stroke, epilepsy, depression, bipolar disorder, COPD, autoimmune disorders, and diabetes. Ion channels are not only important drug targets, but they are also critically important in evaluating drug safety. Many drugs withdrawn from the market due to cardiac-related adverse effects have been shown to block the human ether-a-go-go (hERG) ion channel, which delays repolarization of the cardiac action potential and can result in a potentially fatal arrhythmia known as Torsades de Pointes (TdP).
Eurofins Discovery was the first CRO to provide testing by automated electrophysiology. Since then, we’ve continued to provide industry leadership and collaboration in ion channel functional and binding services. Our LeadHunter® and SafetyScreen™ services are based on a broad collection of over 70 validated voltage-gated and ligand-gated ion channel PrecisION™ cell lines from Eurofins DiscoverX®.
Our reputation is based on exceptional quality standards and the scientific experience required to support the complex nature of ion channel biology—we are a resource at all stages of your drug discovery and safety profiling needs through a wide range of technology services, including high-throughput and rapid turn-around-time (TAT) options.
- Ion Channel Binding
- Manual Patch Clamp (MPC)
- Automated Patch Clamp – Voltage Gated
- Automated Patch Clamp (APC) – Ligand-gated
- Calcium Flux
- Membrane Potential
- Multi-Electrode Array (MEA) Assay
Work with our global science team with access to a broad range of technologies spanning three continents. For service inquiries through all stages of your drug discovery cascade, reach out to our team.
Learn more from this webinar by Fluxion: Pharmacological Characterization of a Primary Nicotinic Receptor from Neuromuscular Junction.
